Deals
Cytiva’s FlexFactory deal with Yoshindo will establish domestic biosimilar manufacturing in Japan by 2028, as the firm pivots from JV-led development toward in-house production amid growing demand and policy support for lower-cost biologics.
Following a deal with Tesaro in January, Alteogen inks another global out-licensing agreement for its subcutaneous delivery enabling platform technology, this time with Biogen.
Its latest acquisition adds to Merck’s arsenal of hemato-oncology candidates, with TERN-701 aiming to challenge Novartis's Scemblix.
Clinical evidence points to immune system ‘reset’ and durable remission. Investors have taken note and the deals have followed.
Bio-Thera has added India to its BAT2506 partnership with Intas, granting exclusive commercialization rights and expanding a global network spanning the US and Canada, as the firm builds its presence in the emerging golimumab biosimilars market.
“Four or five major acquisitions over the last few years repositioned it, a 140-year-old company, from being a B-to-B company to B-to B-to-C company. That is a major enterprise strategy shift,” says CEO Patrick Lockwood-Taylor.
“In a very siloed organization made up of a jigsaw of different companies, no one was thinking enterprise first,” says Perrigo CEO Patrick Lockwood-Taylor. “The fundamentals of running operations, brand-building, innovation, they are now as they were.”
Deal Snapshot: The French drugmaker gains rights to the anti-CD19xBCMAxCD3 candidate, which is designed to have the benign safety profile considered especially important in immunology.
More than a dozen semaglutide generics hit the Indian market at sharp discounts post LOE for Novo Nordisk’s GLP-1 RA molecule setting the stage for a high-octane battle in the diabetes and obesity segment. Can Novo hold steady amid the avalanche and what are KOLs looking for?
Chugai’s partnering office in South San Francisco advances the Japanese company’s business development activities in the US beyond its venture fund established in Boston in 2023.
At opening session of CHPA’s annual Self-Care Leadership Summit on March 17 in Orlando, it presented Fuad Sawaya its highest honor named for Ivan Combe, an industry pioneer who served on its board from 1958 until 2000.
Formycon expects its aflibercept biosimilar to enter European markets from the end of spring, as commercial paths also open up in Latin America and Asia Pacific countries.